scholarly journals Economics of individualization in comparative effectiveness research and a basis for a patient-centered health care

2011 ◽  
Vol 30 (3) ◽  
pp. 549-559 ◽  
Author(s):  
Anirban Basu
2012 ◽  
Vol 33 (1) ◽  
pp. E7 ◽  
Author(s):  
Laura P. D'Arcy ◽  
Eugene C. Rich

Containing growth in health care expenditures is considered to be essential to improving both the long-term fiscal outlook of the federal government and the future affordability of health care in the US. As health care expenditures have increased, so too have concerns about the quality of health care. Better information on the clinical effectiveness of alternative treatments and other interventions is needed to improve the quality of care and restrain growth in expenditures. This article explains the key role played by the federal government in defining the context and process of comparative effectiveness research as well as its funding. Subsequently, the article explores the mission, priorities, and research agenda of the Patient-Centered Outcomes Research Institute, which is an independent, nonprofit corporation established in 2010 by the Patient Protection and Affordable Care Act.


2012 ◽  
Vol 30 (34) ◽  
pp. 4267-4274 ◽  
Author(s):  
Corinna Sorenson ◽  
Michael Drummond ◽  
Kalipso Chalkidou

Purpose To assess the relevance of the experience of the National Institute for Health and Clinical Excellence (NICE) in the United Kingdom to the comparative effectiveness research (CER) initiative in the United States. Methods The activities of NICE were reviewed to assess its experience in analytic methods, engagement with stakeholders, communication of findings, and implementation of recommendations. Results The main lessons for the United States from the experience of NICE relate to how the institute has gathered, synthesized, and used information on the clinical and cost effectiveness of health care interventions. The experience of NICE suggests that ways will have to be found to reconcile the differing stakeholder perspectives on the value of health care. Given the emphasis in the United States on being patient centered, there will be situations where patients' expectations for the provision of care far exceed that which payers feel should be made available on grounds of value for money. Explicit restrictions on access to care based on CER like those found in the United Kingdom are unlikely, but alternative solutions, such as value-based reimbursement, will need to be pursued if unnecessary expenditures are to be avoided. It will also be important that the CER initiative show some impact on the use of health care resources. The longer that NICE has been in existence in the United Kingdom, questions about its impact have been more frequently asked, given the resources devoted to its activities. Conclusion Although there are distinct differences between the health systems of the United Kingdom and United States, lessons can be learned from examining the successes and challenges experienced by NICE.


2018 ◽  
Vol 4 (1) ◽  
Author(s):  
Evan Mayo-Wilson ◽  
Asieh Golozar ◽  
Terrie Cowley ◽  
Nicole Fusco ◽  
Gillian Gresham ◽  
...  

2012 ◽  
Vol 30 (34) ◽  
pp. 4194-4201 ◽  
Author(s):  
Olwen M. Hahn ◽  
Richard L. Schilsky

Comparative effectiveness research (CER) has been promoted as a way to improve the translation gap between clinical research and everyday clinical practice as well as to deliver more cost-effective health care. CER will account for a significant portion of funding allocated by the US government for health care research. Oncology has a rich history of improving clinical outcomes and advancing research through randomized controlled trials (RCTs). In this article, we review the role of RCTs in achieving the goals of CER, with particular emphasis on the role of publicly funded clinical trials.


Sign in / Sign up

Export Citation Format

Share Document